SPECIAL NOTICE
99 -- TECHNOLOGY/BUSINESS OPPORTUNITY Instrumented Neurovascular Unit Device
- Notice Date
- 8/8/2024 12:16:01 PM
- Notice Type
- Special Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- LLNS � DOE CONTRACTOR Livermore CA 94551 USA
- ZIP Code
- 94551
- Solicitation Number
- IL-13964
- Response Due
- 9/8/2024 2:00:00 PM
- Archive Date
- 09/23/2024
- Point of Contact
- Yash Vaishnav, Phone: 9254223538, Charlotte Eng, Phone: 9254221905
- E-Mail Address
-
vaishnav1@llnl.gov, eng23@llnl.gov
(vaishnav1@llnl.gov, eng23@llnl.gov)
- Description
- Opportunity: Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration to further develop and commercialize its �Instrumented Neurovascular Unit Device� technology. Background: A highly controlled microenvironment is required to promote the normal functioning of the central nervous system (CNS). The blood-brain barrier (BBB) is evolved to ensure such a control. It is a biological barrier at the blood to brain interface that effectively separates the brain from the rest of the body, thus able to protect the CNS against pathogens, toxins and xenobiotics. Many CNS pathological conditions are reported to have a defective BBB. These include multiple sclerosis, amyotrophic lateral sclerosis, hypoxic and ischemic insult, Parkinson�s and Alzheimer�s disease, epilepsy, brain tumors, glaucoma, and lysosomal storage diseases. There is an unmet need for an effective in vitro model of the neurovascular unit (NVU) that can both recapitulate and monitor physiologically relevant changes to both the BBB and brain function.� The NVU would provide a powerful platform to study neurological diseases, existing and emerging chemical and biological threats, and for development and evaluation of new brain therapeutics. Description: LLNL inventors have developed a proprietary concept and a prototype NVU device that provides an effective in vitro model of the BBB to discover, develop and screen drug candidates for their ability to cross the BBB. The device could also be useful in studying neurological disorders with defects in BBB to understand the mechanism underlying the pathology of the disease that might reveal modalities of therapeutic intervention. The NVU device provides a means of culturing or co-culturing cells from the CNS in 3D and studying responses to electrical and chemical stimuli in a physiologically relevant manner with features that mimic BBB. Advantages/Benefits:� The NVU device has specific advantages as it: supports neuronal co-cultures in a hydrogel directly in contact with endothelial cells deposited on the inner surface of a microfluidic channel formed through the hydrogel allows static or continuous flow through the vascular channel incorporates 3D multielectrode arrays (MEAs) to non-invasively interrogate the neuronal coculture, and interfaces with commercial electrophysiology instrumentation. Potential Applications:� The device has broad applications in the area of research and testing of drugs using 3D cell culture, particularly in neuroscience area and specifically for testing the ability of a drug candidate to cross the blood-brain barrier. Additional areas include neuronal communication in 3D, blood brain barrier dysfunction, drug development, drug permeability, countermeasure validation, neuroinflammation, pathogen infection, chemical exposure, response of electroactive cells in 3D, disease research (Alzheimer's, Parkinson's, epilepsy, TBI, ALS etc.), recording/stimulation of spheroids/organoids, and microfluidic delivery of chemicals in 3D. Development Status:� Current stage of technology development:� TRL 2 LLNL has filed for patent protection on this invention. LLNL is seeking industry partners with a demonstrated ability to bring such inventions to the market. Moving critical technology beyond the Laboratory to the commercial world helps our licensees gain a competitive edge in the marketplace. All licensing activities are conducted under policies relating to the strict nondisclosure of company proprietary information.� Please visit the IPO website at https://ipo.llnl.gov/resources for more information on working with LLNL and the industrial partnering and technology transfer process. Note:� THIS IS NOT A PROCUREMENT.� Companies interested in commercializing LLNL's Instrumented Neurovascular Unit Device should provide an electronic OR written statement of interest, which includes the following: Company Name and address. The name, address, and telephone number of a point of contact. A description of corporate expertise and/or facilities relevant to commercializing this technology. Please provide a complete electronic OR written statement to ensure consideration of your interest in LLNL's Instrumented Neurovascular Unit Device.� The subject heading in an email response should include the Notice ID and/or the title of LLNL�s Technology/Business Opportunity and directed to the Primary and Secondary Point of Contacts listed below. Written responses should be directed to: Lawrence Livermore National Laboratory Innovation and Partnerships Office P.O. Box 808, L-779 Livermore, CA� 94551-0808 Attention:�� IL-13964
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/ee3b566132a84759ad0f1157d25033b6/view)
- Place of Performance
- Address: Livermore, CA, USA
- Country: USA
- Country: USA
- Record
- SN07161853-F 20240810/240808230115 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |